# XBiotech Inc.: Form 10-Q for the period ended Mar 31, 2017

- Company: [XBiotech Inc.](/companies/xbit.md) (CIK 1626878)
- Form: 10-Q
- Filed: 2017-05-10
- Accepted by EDGAR: May 10, 2017, 16:35 ET
- Period: 2017-03-31
- Accession: 0001171843-17-002928
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1626878/000117184317002928/f10q_051017p.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1626878/000117184317002928/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2017-01-01 to 2017-03-31 | $8.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2017-01-01 to 2017-03-31 | −$10.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2017-01-01 to 2017-03-31 | −$10.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-01-01 to 2017-03-31 | −$0.32 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2017-01-01 to 2017-03-31 | −$11.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2017-01-01 to 2017-03-31 | $607.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2017-03-31 | $54.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-03-31 | $57.1m | us-gaap:AssetsCurrent |
| Total assets | at 2017-03-31 | $87.6m | us-gaap:Assets |
| Current liabilities | at 2017-03-31 | $5.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-03-31 | $5.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2017-03-31 | $82.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 17,157 characters.

### MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### Overview

XBiotech Inc. (“XBiotech” or the “Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human™ pipeline and manufacturing system.

We have never been profitable and, as of March 31, 2017, we had an accumulated deficit of $194.0 million. We had net losses of $10.6 million and $10.3 million for three months ended March 31, 2017 and 2016, respectively. We expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we add personnel and continue to operate as a public company. We will need to generate significant revenues to achieve profitability, and we may never do so. As of March 31, 2017, we had 103 employees.

### Recent Events:

### Clinical trial and construction of the new manufacturing facility Highlights

As of March 2017, XBiotech has achieved some significant milestones with its lead product candidate and 514G3 programs. A Phase III symptomatic colorectal cancer study has been completed and XBiotech proceeded with the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in March 2016. The Company recently announced that the EMA rendered a negative “trend vote” after an Oral Explanation meeting (“OE”) with the Company to discuss the remaining outstanding objections related to the Company’s MAA. A negative trend vote means it is unlikely that a positive Committee for Medicinal Products for Human Use (CHMP) opinion related to the Company’s MAA will be attained at the formal decision vote scheduled in May, and that additional steps would need to be taken to potentially gain marketing approval.

XBiotech also completed enrollment in a second Phase III study, a double-blind placebo controlled study for improving survival in metastatic colorectal cancer. More than 600 patients were randomized in over twenty countries globally and the first interim analysis was successfully completed in February 2017. The second interim analysis is planned in mid June 2017. Furthermore, XBiotech successfully completed its global staphylococcus aureus (*S. aureus*) bacteremia phase I/ II study with 514G3, a novel True Human™ therapeutic antibody for treating serious infections due to *S. aureus* and announced top-line results from the study in April.

In August 2016, the Company completed construction of the new manufacturing facility located in Austin, Texas. The 40,000 square foot facility will provide a significant increase in the Company’s manufacturing and quality operations for production of the Company’s product pipeline. The new facility has increased about ten-fold the Company’s current production capacity.

The Company continues to be subject to a number of risks common to companies in similar stages of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. The Company’s ability to fund its planned clinical operations, including completion of its planned clinical trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and/or financing transactions. The Company believes that its cash and cash equivalents of $54.6 million at March 31, 2017 will enable the Company to achieve several major inflection points, including potential marketing authorization in Europe, completion of ongoing clinical studies in oncology and infectious disease, as well as launching its new manufacturing center. Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of March 31, 2017 will enable us to fund our operating expenses and capital expenditure requirements through the end of 2018. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

### Revenues

To date, we have not generated any revenue. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize our lead product candidate, Xilonix™, or any other product candidate we may advance in the future.

### Research and Development Expenses

Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, stock-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operations as incurred.

Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through March 31, 2017, we have recorded total research and development expenses, including share-based compensation, of $151.8 million. Our total research and development expenses for the three months ended March 31, 2017 and 2016 were $8.2 million and $7.8 million, respectively. Share-based compensation accounted for $0.3 million and $0.6 million for the three months ended March 31, 2017 and 2016, respectively.

Research and development expenses, as a percentage of total operating expenses for the three months ended March 31, 2017 and 2016 were 80% and 76%, respectively. The percentages, *excluding* stock-based compensation, for the three months ended March 31, 2017 and 2016, were 83% and 86%, respectively.

As planned, our clinical development costs increased as we advanced our lead product candidate as an anti-cancer therapy for treating last-line metastatic colorectal cancer (mCRC), under a regulatory pathway through global phase III clinical trials under EMA and FDA jurisdictions.

The clinical research and development costs may decrease going forward with the completion of the Phase I/II *S. aureus* Bacteremia study and as we enter the maintenance phase of the FDA pivotal phase III mCRC trial. Although, expenses could increase due to potential marketing approval of our lead product candidate in Europe and related commercialization costs, as well as, the potential of pursuing advanced clinical studies in various indications.

Based on the results of our preclinical studies, we anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. For research and development candidates in early stages of development, it is premature to estimate when material net cash inflows from these projects might occur.

### General and Administrative Expenses

General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, and professional fees for legal services. Our total general and administration expenses for the three months ended March 31, 2017 and 2016 were $2.1 million and $2.4 million, respectively. Share-based compensation accounted for $0.4 million and $1.2 million for the three months ended March 31, 2017 and 2016, respectively.

General and administrative expense, as a percentage of total operating expenses for the three months ended March 31, 2017 and 2016 were 20% and 24%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2017 and 2016, were 17% and 14%, respectively.

### Critical Accounting Policies

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our consolidated financial statements and accompanying notes. Actual results could differ from those estimates. We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2016.

### Results of Operations

### Revenue

We did not record any revenue during the three months ended March 31, 2017 and 2016.

### Expenses

#### Research and Development

Research and Development costs are summarized as follows (in thousands):

|  | Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $2,213 | $1,858 | $355 | 19% |
| Laboratory and manufacturing supplies | 1,232 | 776 | 456 | 59% |
| Clinical trials and sponsored research | 3,155 | 3,656 | (501) | (14%) |
| Stock-based compensation | 294 | 597 | (303) | (51%) |
| Other | 1,294 | 925 | 369 | 40% |
| Total | $8,188 | $7,812 | $376 | 5% |

We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.

Research and development expenses increased by $0.4 million to $8.2 million for the three months ended March 31, 2017, compared to $7.8 million for the three months ended March 31, 2016. There was a decrease in clinical trials and sponsored research due to the clinical trial expense accrual. A continued increase in laboratory and manufacturing supplies expense occurred due to the increase of manufacturing processing development activities, research activities, quality control activities and the validation of equipment in the new manufacturing facility. Labor costs also increased due to the growing size of the research and development workforce from 75 to 93. We also incurred $276 thousand increase in facility expense due to the facility expense incurred in the new manufacturing building.

#### General and Administrative

General and administrative costs are summarized as follows (in thousands):

|  | Three Months Ended March 31, 2017 | 2016 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $469 | $527 | $(58) | (11%) |
| Patent filing expense | 186 | 146 | 40 | 27% |
| Stock-based compensation | 430 | 1,219 | (789) | (65%) |
| Professional fees | 415 | 92 | 323 | 351% |
| Other | 583 | 452 | 131 | 29% |
| Total | $2,083 | $2,436 | $(353) | (14%) |

18

General and administrative expense decreased $0.3 million to $2.1 million for the three months ended March 31, 2017, compared to $2.4 million for the three months ended March 31, 2016. The decrease was primarily related to stock–based compensation expenses of $0.8 million, due to the grant of stock options to board members in 2016 Q1 that were immediately vested. The increase in professional fees was attributable to the commercialization activities in Europe and increased corporate legal fee. Other reasons for increases included insurance and facility expense.

### Other income (loss)

The following table summarizes other income (loss) (in thousands):

|  | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Interest income | 49 | - |
| Foreign exchange loss | $(341) | $(9) |
| Total | $(292) | $(9) |

The $49 thousand of interest income for the three months ended March 31, 2017 is mainly from the interest generated from our Canadian bank account. Foreign exchange loss was mainly due to the fluctuation of the exchange rate between Euro and US dollar.

### Liquidity and Capital Resources

Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments.

Since our inception on March 22, 2005 through March 31, 2017, we have funded our operations principally through the private placement of equity securities, which have provided aggregate cash proceeds of approximately $256.6 million. The following table summarizes our sources and uses of cash (in thousands):

| Net cash (used in) provided by: | Three Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Operating activities | $(11,908) | $(9,947) |
| Investing activities | (607) | (2,917) |
| Financing activities | 32,713 | - |
| Effect of foreign exchange rate on cash and cash equivalents | 110 | 38 |
| Net change in cash and cash equivalents | $20,308 | $(12,826) |

19

During the three months ended March 31, 2017 and 2016, our operating activities used net cash of $11.9 million and $9.9 million, respectively. The use of net cash in each of these periods primarily resulted from our net losses. The increase in net loss from operations for the three months ended March 31, 2017 as compared to the three months ended March 31, 2016 was mainly due to increases in laboratory and manufacturing supplies, research and development labor and facility expense.

During the three months ended March 31, 2017 and 2016, our investing activities used net cash of $0.6 million and $2.9 million, respectively. The use of cash during the three months ended March 31, 2017 was for the purchase of new research and development equipment. We spent approximately $2.6 million on the construction of new facilities during the three months ended March 31, 2016.

During the three months ended March 31, 2017, our financing activities provided net cash proceeds of $32.7 million and no cash was provided in the three months ended March 31, 2016. During the three months ended March 31, 2017, we entered into subscription agreements with accredited investors, and sold 2.4 million common shares at $13 per share for approximately $31.6 million in net proceeds. Also, we sold 87 thousand shares under a Common Stock Sales Agreement with H.C. Wainwright & Co. LLC for net proceeds of approximately $1.0 million. Employees exercised stock options to purchase a total of 66 thousand shares of common stock for a total of approximately $0.3 million in net proceeds.

We expect to continue to incur substantial operating losses in the future. We will not receive any product revenue until a drug candidate has been approved by the Food and Drug Administration or similar regulatory agencies in other countries and successfully commercialized. As of March 31, 2017, our principal sources of liquidity were our cash and cash equivalents, which totaled approximately $54.6 million.

### Contractual Obligations and Commitments

On January 12, 2008, we entered a lease agreement to lease our facility in Austin, Texas. On September 15, 2010, we entered into a second lease agreement to lease additional space in Austin, Texas. On March 20, 2014, we extended the lease for an additional 21 months on the same terms and rental rates as the current lease. On February 28, 2016, we extended the lease for another 4 years. The future minimum lease payments are as follows as of March 31, 2017 (in thousands):

| Contractual Obligations | Total | Less than 1 Year | 1 - 3 Years | More than 3 years |
| --- | ---: | ---: | ---: | ---: |
| Operating facility leases | $896 | $463 | $433 | $— |
| Total contractual obligations | $896 | $463 | $433 | $— |

Rent expense was $186 thousand and $179 thousand for the three months ended March 31, 2017 and 2016, respectively.

### Off-Balance Sheet Arrangements

Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

## Market risk

As filed, 308 characters.

The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.

## Controls and procedures

As filed, 1,804 characters.

### Management's Evaluation of our Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.

### Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the first quarter of the year ended December 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

## Risk factors

As filed, 837 characters.

There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2016. Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our Common Stock. Additional risks not currently known or currently material to us may also harm our business.

Filed May 10, 2017.
Source: SEC EDGAR, the filing index for accession 0001171843-17-002928. Last ingested by Listed: Nov 14, 2026, 18:14 ET. No prices; not investment advice.
